SCHEMBL4495643

SCHEMBL4495643

O=C(O)[C@@H]1CNC[C@H](NCc2cccc(Cl)c2)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.48
CARM1 Q86X55 2/20 0.44
PRMT6 Q96LA8 2/20 0.44
TAAR1 Q96RJ0 3/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
SLC6A11 P48066 1/20 0.43
GLA P06280 1/20 0.43
GRM2 Q14416 1/20 0.43
GRM3 Q14832 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
ALOX12 P18054 1/20 0.43
EPHX2 P34913 1/20 0.42
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4495638 1.00 RXFP1 (0.48) RXFP1CARM1PRMT6TAAR1TP53
SCHEMBL1913240 0.84 REN (0.52) RXFP1POLBGABRPGABRDGABRA1
SCHEMBL4574649 0.79 CARM1 (0.50) RXFP1CARM1PRMT6MAPTALOX12
SCHEMBL4507105 0.78 NPC1 (0.49) TP53POLBSLC6A11ALDH1A1
SCHEMBL4507102 0.78 NPC1 (0.49) TP53POLBSLC6A11ALDH1A1
SCHEMBL4498225 0.77 SLC6A2 (0.45) RXFP1TAAR1TP53POLBGLA
SCHEMBL4498217 0.77 SLC6A2 (0.45) RXFP1TAAR1TP53POLBGLA
SCHEMBL4503627 0.74 HDAC8 (0.50) ALDH1A1
SCHEMBL4502020 0.74 MEN1 (0.60) POLBALDH1A1MAPTEPHX2
SCHEMBL4502018 0.74 MEN1 (0.60) POLBALDH1A1MAPTEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US claimed
EP-1907359-A2 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS Novartis AG (CH) 2008-04-09 EP claimed
WO-2007006534-A2 PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY NOVARTIS AG (CH) 2007-01-18 WO claimed
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233920-A1 ORGANIC COMPOUNDS REN, ACE, AGTR1 RXFP1 209/4885CARM1 924/4885PRMT6 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.